Critical Comparison: Mediwound (MDWD) versus GLG Life Tech (GLGLF)

Mediwound (NASDAQ:MDWD) and GLG Life Tech (OTCMKTS:GLGLF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mediwound and GLG Life Tech, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mediwound 0 0 3 0 3.00
GLG Life Tech 0 0 0 0 N/A

Mediwound currently has a consensus price target of $11.33, suggesting a potential upside of 100.59%. Given Mediwound’s higher possible upside, equities research analysts plainly believe Mediwound is more favorable than GLG Life Tech.

Institutional & Insider Ownership

32.6% of Mediwound shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Mediwound has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Comparatively, GLG Life Tech has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.

Valuation and Earnings

This table compares Mediwound and GLG Life Tech’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mediwound $2.50 million 61.13 -$22.14 million ($0.62) -9.11
GLG Life Tech $14.95 million 1.79 -$12.98 million N/A N/A

GLG Life Tech has higher revenue and earnings than Mediwound.

Profitability

This table compares Mediwound and GLG Life Tech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mediwound -783.30% -210.90% -33.92%
GLG Life Tech -101.81% N/A -35.91%

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

GLG Life Tech Company Profile

GLG Life Tech Corporation manufactures and sells refined forms of stevia and monk fruit extracts under the ClearTaste brand name in China and North America. It also offers P-Pro Plus, a pea protein powder; and sources and sells natural and functional food ingredients, such as pea protein, rice bran, rice protein, erythritol, inositol, inulin, and lycopene for food and beverage companies, as well as for cosmetic industry under the Naturals+ name. The company was formerly known as GLG Life Tech Limited and changed its name to GLG Life Tech Corporation in March 2007. GLG Life Tech Corporation was incorporated in 1998 and is headquartered in Richmond, Canada.

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply